(Q38460865)

3 September 2017

1 reference

title

Glioblastoma: pathology, molecular mechanisms and markers (English)

1 reference

3 September 2017

1 reference

5

Andreas von Deimling

0 references

Guido Reifenberger

series ordinal

4

object named as

Guido Reifenberger

1 reference

3 September 2017

Kenneth Aldape

1

1 reference

3 September 2017

Gelareh Zadeh

series ordinal

2

1 reference

3 September 2017

Sheila Mansouri

series ordinal

3

1 reference

3 September 2017

language of work or name

1 reference

6 May 2015

1 reference

3 September 2017

published in

Acta Neuropathologica

1 reference

3 September 2017

volume

129

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

829-848

1 reference

https://scigraph.springernature.com/pub.10.1007/s00401-015-1432-1

3 September 2017

exact match

0 references

cites work

Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

TP53 promoter methylation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

PTEN methylation and expression in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

A distinct spectrum of copy number aberrations in pediatric high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

G-cimp status prediction of glioblastoma samples using mRNA expression data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Early accelerated approval for highly targeted cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

TP53 Gene Mutations and 17p Deletions in Human Astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

A human brain tumor-derived PDGFR-alpha deletion mutant is transforming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

IDH mutations in glioma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Platelet-derived growth factor and its receptor expression in human oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Regulation of the human telomerase reverse transcriptase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Emerging insights into the molecular and cellular basis of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The integrated landscape of driver genomic alterations in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Gene expression profiling of gliomas strongly predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

TERT promoter mutations in familial and sporadic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Genomic imprinting mechanisms in mammals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Different angiogenic phenotypes in primary and secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Epithelioid GBMs show a high percentage of BRAF V600E mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Long-term survival with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Pten haploinsufficiency accelerates formation of high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Clinicopathologic and genomic features of gliosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Expanding chemical biology of 2-oxoglutarate oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Promoter hypermethylation of the RB1 gene in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

DNA methylation and chromatin modification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The definition of primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Addressing diffuse glioma as a systemic brain disease with single-cell analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

A vaccine targeting mutant IDH1 induces antitumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Pediatric glioblastomas: a histopathological and molecular genetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Epidemiologic and molecular prognostic review of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Distinct transcription profiles of primary and secondary glioblastoma subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Frequency of TERT promoter mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1432-1

10.1007/S00401-015-1432-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1029275913

0 references

1 reference